数据链接：
官方服务：
资源简介：
Triple-modality autoantibody reduction regimen.
应用场景：
创建时间：
2021-11-23
相关数据集
Discovery of KT-474a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases
Interleukin-1 receptor associated kinase 4 (IRAK4) is an essential mediator of the IL-1R and TLR signaling pathways, both of which have been implicated in multiple autoimmune conditions. Hence, blocki
NIAID Data Ecosystem40
Immune ablation and stem-cell therapy in autoimmune disease: Introduction
Immune ablation and stem-cell therapy in autoimmune disease: Introduction
data.gov30
Conversion of antigen-specific effector/memory T cells into Foxp3-expressing Treg cells by inhibition of CDK8/19. Mus musculus strain:Balb/c
A promising way to harness hazardous immune responses, such as autoimmune disease and allergy, is to convert disease-mediating T cells into immuno-suppressive regulatory T (Treg) cells. Here we show t
NIAID Data Ecosystem20
DataSheet_6_Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects.pdf
BackgroundParenteral anti-CD3 Mab (OKT3) has been used to treat transplant rejection and parental administration of a humanized anti-CD3 Mab (Teplizumab) showed positive effects in diabetes. Nasal adm
NIAID Data Ecosystem30
DataSheet_1_Tolerogenic Immunomodulation by PEGylated Antigenic Peptides.pdf
Current treatments for autoimmune disorders rely on non-specific immunomodulatory and global immunosuppressive drugs, which show a variable degree of efficiency and are often accompanied by side effec
NIAID Data Ecosystem30
